| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Immunovant, Inc. | Director | Common Stock | 25,016 | $367,234 | $14.68 | 01 May 2025 | Direct |
| BridgeBio Oncology Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 138,193 | 26 Aug 2025 | Direct | ||
| Immunovant, Inc. | Director | Stock Option (Right to Buy) | 35,234 | 01 May 2025 | Direct | ||
| Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 20,491 | 06 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| HLXB | BridgeBio Oncology Therapeutics, Inc. | 26 Aug 2025 | 1 | $0 | 4 | Director | 28 Aug 2025, 16:41 |
| HLXB | BridgeBio Oncology Therapeutics, Inc. | 11 Aug 2025 | 0 | $0 | 3 | Director | 18 Aug 2025, 17:14 |
| IMVT | Immunovant, Inc. | 01 May 2025 | 2 | $0 | 4 | Director | 05 May 2025, 19:30 |
| IMVT | Immunovant, Inc. | 18 Apr 2025 | 0 | $0 | 3 | Director | 28 Apr 2025, 17:02 |
| ELVN | Enliven Therapeutics, Inc. | 06 Feb 2025 | 1 | $0 | 4 | Director | 10 Feb 2025, 17:34 |
| ELVN | Enliven Therapeutics, Inc. | 13 Feb 2024 | 1 | $0 | 4/A | Director | 20 Feb 2024, 19:26 |
| ELVN | Enliven Therapeutics, Inc. | 13 Feb 2024 | 1 | $0 | 4 | Director | 15 Feb 2024, 20:44 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | Director | 06 Apr 2023, 20:16 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 2 | $0 | 4 | Director | 27 Feb 2023, 20:51 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 0 | $0 | 3 | Director | 27 Feb 2023, 20:44 |
| /report/000114036121024134-bauer-jake-2021-07-12 | ARYA Sciences Acquisition Corp V | 12 Jul 2021 | 0 | $0 | 3 | Director | 12 Jul 2021, 19:54 |